Working... Menu

Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00483327
Recruitment Status : Completed
First Posted : June 7, 2007
Results First Posted : July 1, 2016
Last Update Posted : April 4, 2018
Information provided by (Responsible Party):
NYU Langone Health

Brief Summary:
The purpose of this trial is to study the efficacy, toxicity, and tolerability of a standard hormonal regimen of Megestrol Acetate (Megace) in the treatment of Atypical Endometrial Hyperplasia or well to moderately differentiated endometrial carcinoma.

Condition or disease Intervention/treatment Phase
Atypical Endometrial Hyperplasia Endometrial Carcinoma Drug: Megestrol Acetate Phase 2

Detailed Description:

The trial's objectives are to study the efficacy, defined as complete pathologic resolution of disease, of a standard hormonal regimen with the progestin Megace for the treatment of atypical endometrial hyperplasia or well or moderately differentiated endometrial carcinoma in women desiring conservative medical management of these conditions in the Women's Cancer Program at the NYU School of Medicine and at the Bellevue Gynecologic Oncology clinics.

The major endpoint is pathologic complete response (pCR). For the purposes of this study, patients will be reevaluated for response every 12 weeks until complete response. Response will be assessed within 4 weeks of completion of 12 weeks of Megace, by endometrial biopsy or dilation and curettage (D&C)/hysteroscopy. An endometrial biopsy is sufficient to document progressive, stable disease or partial response. A D&C is necessary to confirm complete response.

Patients whose disease has completely responded will discontinue treatment and be encouraged to pursue fertility. Those not desiring immediate fertility will be placed on low dose oral contraceptive pills for at least 6 months. Patients who have had either a partial response or stable disease will be recounseled and offered continued medical management or surgical therapy. Patients whose disease has progressed will be offered definitive surgical management. Those patients declining surgery will still be followed on study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective Trial of Conservative Management of Atypical Endometrial Hyperplasia and Well to Moderately Differentiated Endometrial Carcinoma Using Megestrol Acetate
Study Start Date : June 2007
Actual Primary Completion Date : October 2013
Actual Study Completion Date : October 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Megestrol Acetate
80 mg (2 tablets) orally at breakfast, 80 mg at dinner for at least 12 weeks and up to 2 years.
Drug: Megestrol Acetate
Other Name: Megace

Primary Outcome Measures :
  1. Best Pathologic Responses [ Time Frame: up to 24 months ]
    Patients are evaluated every 12 weeks while on treatment. The response is evaluated by endometrial biopsy or dilation and curettage (D&C)/hysteroscopy. Complete response (CR) is defined as endometrial sampling is read as normal or proliferative endometrium. Partial response (PR) is defined as the biopsy sample has changed on the endometrial evaluation scale by at least one level towards normal. Stable disease (SD) is defined as no change in pathology between the index and follow-up sample. Progressive disease (PD) is defined the follow-up sample has changed towards neoplasia on the endometrial evaluation scale by at least one level or imaging is concerning for myometrial invasion or extrauterine disease such that conservative management is no longer medically appropriate.

Secondary Outcome Measures :
  1. Toxicity and Tolerability [ Time Frame: up to 36 months ]
    Patients with adverse events (AEs) which were possibly, probably, or definitely related to the treatment. AEs were evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) 3.

  2. Duration of Response [ Time Frame: up to 4 years ]
    For each patient, assessed every 12 weeks during treatment and every 6 months during follow-up.

  3. Number of Women Who Became Pregnant [ Time Frame: up to 3 years after the treatment for each patient ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women with a diagnosis of atypical endometrial hyperplasia or G1 or G2 endometrial carcinoma confirmed by an New York University (NYU) pathologist desiring medical management will be eligible. The diagnosis may be obtained either by endometrial biopsy or D&C. If diagnosis has been made outside of NYU, slides must be available for review.
  • Age > = 18 years.
  • Life expectancy of greater than 12 months.
  • Gynecologic Oncology Group (GOG) performance status score of 0, 1 or 2
  • Patients must have normal organ and marrow function as defined below:

    • leukocytes > = 3,000/mcL
    • platelets > = 100,000/mcL
    • total bilirubin within normal institutional limits
    • AST(SGOT)/ALT(SGPT) no greater than 2.5 X institutional upper limit of Normal
    • glucose < 200 mg/dl
    • creatinine within normal institutional limits OR
    • creatinine clearance > = 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
  • Eligibility of patients receiving any medications or substances known to affect or with the potential to affect the activity or pharmacokinetics of Megace will be determined following review of their case by the Principal Investigator.
  • The effects of Megace on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because Megace is known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Patients with a histological diagnosis of clear cell, papillary serous or poorly differentiated (G3) endometrial carcinoma.
  • Patients with cancer have an MRI showing evidence of extrauterine spread or myometrial invasion.
  • Presence of US findings suspicious for ovarian malignancy, unclear endometrial primary or recurrent endometrial cancer.
  • Patients receiving other investigational agents.
  • Patients with a history of a previous thrombotic event, known thrombophilic condition or poorly controlled diabetes.
  • Patients with a history of breast cancer or other hormonally responsive malignancy.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant women are excluded from this study because Megace has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with Megace, breastfeeding should be discontinued if the mother is treated with Megace.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00483327

Layout table for location information
United States, New York
Bellevue Hospital
New York, New York, United States, 10016
NYU Cancer Center
New York, New York, United States, 10016
Sponsors and Collaborators
NYU Langone Health
Layout table for investigator information
Principal Investigator: Stephanie V Blank, M.D. New York University

Layout table for additonal information
Responsible Party: NYU Langone Health Identifier: NCT00483327     History of Changes
Other Study ID Numbers: 06-685
First Posted: June 7, 2007    Key Record Dates
Results First Posted: July 1, 2016
Last Update Posted: April 4, 2018
Last Verified: March 2018

Keywords provided by NYU Langone Health:

Additional relevant MeSH terms:
Layout table for MeSH terms
Endometrial Neoplasms
Endometrial Hyperplasia
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Pathologic Processes
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Diseases
Genital Diseases, Female
Megestrol Acetate
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Appetite Stimulants
Central Nervous System Stimulants